US equities
|
MU
$1,088.00
▲+4.06%
NVDA
$237.47
▼-0.74%
SNDK
$1,692.42
▲+1.92%
SPCX
$167.60
▼-2.51%
AMD
$645.86
▼-0.55%
AAPL
$336.67
▲+0.91%
TSLA
$377.81
▼-0.75%
INTC
$113.12
▲+0.55%
MU
$1,088.00
▲+4.06%
NVDA
$237.47
▼-0.74%
SNDK
$1,692.42
▲+1.92%
SPCX
$167.60
▼-2.51%
AMD
$645.86
▼-0.55%
AAPL
$336.67
▲+0.91%
TSLA
$377.81
▼-0.75%
INTC
$113.12
▲+0.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Voyageur Pharmaceuticals Ltd
(OP:
VYYRF
)
0.0880
-0.0120 (-12.00%)
Delayed Quote
Updated: 3:55 PM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Voyageur Pharmaceuticals Ltd
(PODCAST) Voyageur Pharmaceuticals (TSXV:VM) Achieves First Milestone in Bayer Collaboration, Secures USD $1 Million Payment
September 10, 2026
CALGARY, Alberta — September 10, 2026 — Leads & Copy — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF), a Canadian company focused on developing pharmaceutical-grade barium and iodine...
Via
TheNewswire.com
Topics
Economy
Voyageur Pharmaceuticals Achieves First Milestone on Feasibility Study for Iodine Production; Secures USD $1 Million Payment
September 09, 2026
Via
TheNewswire.com
Topics
Economy
Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Seasoned Financial Executive Virginia Alling to Drive U.S. Market Expansion
November 07, 2025
Via
TheNewswire.com
Voyageur Pharmaceuticals "sees a gap in the market" for domestically-produced barium
September 28, 2023
--News Direct--
Via
News Direct
Voyageur Pharmaceuticals "sees a gap in the market" for domestically-produced barium
September 28, 2023
Proactive Research Analyst Daniel Appiah speaks to Thomas Warner from the Londons studio after publishing a new research note on Canadian medical imaging contrast media company Voyageur Pharmaceuticals...
Via
TheNewswire.com
Voyageur Pharmaceuticals with a "big market to go for"
June 07, 2023
Proactive research analyst John Savin speaks to Thomas Warner after publishing a new research note on Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF), a Canadian company that specialises in...
Via
TheNewswire.com
Voyageur Pharmaceuticals with a "big market to go for"
June 07, 2023
Voyageur Pharmaceuticals with a "big market to go for"
Via
News Direct
Voyageur Pharmaceuticals Partners with Rain Cage Carbon to Revolutionize Medical Imaging with Nanocarbon-Based Contrast Drugs
May 24, 2023
Via
TheNewswire.com
Voyageur Pharmaceuticals Ltd. Announces Update To PEA and a Related New Opportunity To Market High Purity USP Barium Sulfate
August 19, 2021
Calgary, Alberta - TheNewswire - August 19, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") has been working with SGS Canada Inc. on the Preliminary Economic...
Via
TheNewswire.com
Voyageur Pharmaceuticals Announces Board of Director Changes and 2nd quarter Financial Results
July 26, 2021
Calgary, Alberta - TheNewswire - July 26th, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the “Company” or “Voyageur”). Voyageur is very pleased to announce that Frank Wright and Ralph...
Via
TheNewswire.com
Voyageur Pharmaceuticals Ltd. Announces Completion of Private Placement
June 14, 2021
Calgary, Alberta - TheNewswire - June 14, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") announces that, further to news releases dated April 13 and 23, and...
Via
TheNewswire.com
Voyageur Pharmaceuticals Ltd. Announces Closing of Second Tranche of Private Placement
May 28, 2021
Calgary, Alberta – TheNewswire - May 28, 2021 – Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC:VYYRF) (the "Company" or "Voyageur") announces that, further to news releases dated April 13 and 23, 2021...
Via
TheNewswire.com
Voyageur Pharmaceuticals Ltd. Issuance of 5th Product License for MultiXThick Radiographic Barium Contrast
May 17, 2021
Via
Get News
Voyageur Pharmaceuticals Ltd. Announces Health Canada Approval and Issuance of 5th Product License for MultiXThick Radiographic Barium Contrast
May 17, 2021
Calgary, Alberta - TheNewswire - May 17, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada...
Via
TheNewswire.com
Voyageur Pharmaceuticals Ltd. Announces Health Canada Approval and Issuance of Product Licenses for MultiXThin Radiographic Barium Contrast
May 05, 2021
Calgary, Alberta - TheNewswire - May 5, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada...
Via
TheNewswire.com
Voyageur Pharmaceuticals Ltd. Issued 4th Health Canada License For Radiographic Barium Contrast Product
May 04, 2021
Via
Get News
Recent Decision from DC Circuit Court Likely to Result in Less Cost and Faster Approvals for Voyageur Barium Products - Voyageur Hires Team of Experts to Support Product Roll-Out
April 20, 2021
Calgary, Alberta – TheNewswire - April 20, 2021 – Voyageur Pharmaceuticals Ltd. (TSX.V:VM) USA (OTC:VYYRF) (the “Company” or “Voyageur”), is pleased to announce that the D.C. Circuit Court of Appeals
Via
TheNewswire.com
